Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).
Ovarian Cancer|Cervical Cancer
DRUG: Efbemalenograstim Alfa
Incidence of grade 3/4 neutropenia, Incidence of grade 3/4 neutropenia during the first chemotherapy cycle for participants receiving primary prophylaxis with Efgbemalenograstim alfa in the first treatment cycle, At the first of cycle 1 (each cycle is 21 days)
The incidence rate of Grade 3/4 ANC reduction for each cycle, The incidence rate of Grade 3/4 ANC reduction in every treatment cycle, in every treatment cycle( each cycle is 21 days)|The incidence rate of Grade ≥2 ANC reduction for each cycle, The incidence rate of Grade ≥2 ANC reduction in every treatment cycle, in every treatment cycle( each cycle is 21 days)|The incidence rate of FN, The incidence rate of febrile neutropenia (FN) for each cycle, in every treatment cycle( each cycle is 21 days)|Adverse Events, Including adverse events/serious adverse events and their incidence rates, in every treatment cycle( each cycle is 21 days)
This study is a single-arm, multicenter clinical trial. A total of 83 patients will be enrolled, including 55 patients with primary epithelial ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) and 28 patients with primary or recurrent/metastatic cervical cancer in the first-line setting.

1) Ovarian Cancer

Chemotherapy regimen (Paclitaxel + Carboplatin ± Bevacizumab):

Paclitaxel 175mg/m2, intravenous infusion over 3 hours, on day 1; followed by Carboplatin Area under the curve 5(AUC5), intravenous infusion over 1 hour, on day 1; Bevacizumab 7.5-15 mg/kg, on day 1, administered as intravenous infusion; repeated every 3 weeks.

(2) Cervical Cancer

Chemotherapy regimen (Paclitaxel + Carboplatin/Cisplatin ± Bevacizumab):

Paclitaxel 175mg/m2, intravenous infusion over 3 hours, on day 1; followed by Carboplatin AUC5, intravenous infusion over 1 hour, on day 1, or Cisplatin 50-80mg/m2, intravenous infusion over 1-3 hours, on day 1; Bevacizumab 7.5-15 mg/kg, on day 1, administered as intravenous infusion; repeated every 3 weeks.

Efbemalenograstim Alfa should be administered subcutaneously, 20mg per injection, within 24-48 hours after the completion of each chemotherapy cycle.